Eli Lilly and Company is a drug manufacturers - general business based in the US. Eli Lilly and Company shares (LLY) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $826.76 – an increase of 3.13% over the previous week. Eli Lilly and Company employs 47,000 staff and has a trailing 12-month revenue of around $45 billion.
Offer ends 4/1/25. Customer must fund their Active invest account with at least $50 within 30 days of opening the account. Probability of customer receiving $2,000 is 0.028%. See full terms and conditions at https://www.sofi.com/greenintwoterms/.
Open an account.Provide your personal information and sign up.
Fund your account.Deposit funds into your account by linking your banking information or transfer funds from another trading account.
Search for the stock name – LLY.Search for the stock by name or ticker symbol.
Buy the stock. Place your order. It's that simple.
Buy Eli Lilly and Company stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 5 of 5
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Eli Lilly and Company stock price (NYSE: LLY)
Use our graph to track the performance of LLY stocks over time.
Is it a good time to buy Eli Lilly and Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Eli Lilly and Company price performance over time
Historical closes compared with the close of $852.35 from 2025-03-25
1 week (2025-03-19)
1.83%
1 month (2025-02-27)
-5.83%
3 months (2024-12-27)
8.83%
6 months (2024-09-27)
-2.90%
1 year (2024-03-26)
9.99%
2 years (2023-03-24)
157.36%
3 years (2022-03-25)
203.08%
5 years (2020-03-26)
574.42%
Is Eli Lilly and Company stock undervalued or overvalued?
Valuing Eli Lilly and Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Eli Lilly and Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Eli Lilly and Company's P/E ratio
Eli Lilly and Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 72x. In other words, Eli Lilly and Company shares trade at around 72x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Eli Lilly and Company's PEG ratio
Eli Lilly and Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.236. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Eli Lilly and Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Eli Lilly and Company's EBITDA
Eli Lilly and Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.3 billion.
The EBITDA is a measure of a Eli Lilly and Company's overall financial performance and is widely used to measure a its profitability.
Eli Lilly and Company financials
Revenue TTM
$45 billion
Operating margin TTM
42.84%
Gross profit TTM
$36.6 billion
Return on assets TTM
15.33%
Return on equity TTM
84.26%
Profit margin
23.51%
Book value
$15.81
Market Capitalization
$756.8 billion
TTM: trailing 12 months
Eli Lilly and Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Eli Lilly and Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Eli Lilly and Company's total ESG risk score
Total ESG risk: 32.36
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Eli Lilly and Company's overall score of 32.36 (as at 12/31/2018) is pretty weak – landing it in it in the 70th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Eli Lilly and Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Eli Lilly and Company's environmental score
Environmental score: 0.63/100
Eli Lilly and Company's environmental score of 0.63 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Eli Lilly and Company's social score
Social score: 16.68/100
Eli Lilly and Company's social score of 16.68 puts it squarely in the 1st percentile of companies rated in the same sector. This could suggest that Eli Lilly and Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Eli Lilly and Company's governance score
Governance score: 13.31/100
Eli Lilly and Company's governance score puts it squarely in the 1st percentile of companies rated in the same sector. That could suggest that Eli Lilly and Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Eli Lilly and Company's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Eli Lilly and Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Eli Lilly and Company hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Eli Lilly and Company was last rated for ESG on: 2019-01-01.
Total ESG score
32.36
Total ESG percentile
70.22
Environmental score
0.63
Environmental score percentile
1
Social score
16.68
Social score percentile
1
Governance score
13.31
Governance score percentile
1
Level of controversy
3
Eli Lilly and Company share dividends
Dividend payout ratio: 41.54% of net profits
Recently Eli Lilly and Company has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Eli Lilly and Company shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Eli Lilly and Company's case, that would currently equate to about $5.2 per share.
While Eli Lilly and Company's payout ratio might seem fairly standard, it's worth remembering that Eli Lilly and Company may be investing much of the rest of its net profits in future growth.
Eli Lilly and Company's most recent dividend payout was on 9 March 2025. The latest dividend was paid out to all shareholders who bought their shares by 13 February 2025 (the "ex-dividend date").
Have Eli Lilly and Company's shares ever split?
Eli Lilly and Company's shares were
split on a 2:1 basis on 15 October 1997
. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Eli Lilly and Company shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Eli Lilly and Company shares which in turn could have impacted Eli Lilly and Company's share price.
Eli Lilly and Company share price volatility
Over the last 12 months, Eli Lilly and Company's shares have ranged in value from as little as $710.1761 up to $969.2515. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Eli Lilly and Company's is 0.335. This would suggest that Eli Lilly and Company's shares are less volatile than average (for this exchange).
Eli Lilly and Company overview
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc. ; F. Hoffmann-La Roche Ltd and Genentech, Inc.
Frequently asked questions
What percentage of Eli Lilly and Company is owned by insiders or institutions? Currently 0.167% of Eli Lilly and Company shares are held by insiders and 83.561% by institutions.How many people work for Eli Lilly and Company? Latest data suggests 47,000 work at Eli Lilly and Company.When does the fiscal year end for Eli Lilly and Company? Eli Lilly and Company's fiscal year ends in December.Where is Eli Lilly and Company based? Eli Lilly and Company's address is: Lilly Corporate Center, Indianapolis, IN, United States, 46285What is Eli Lilly and Company's ISIN number? Eli Lilly and Company's international securities identification number is: US5324571083What is Eli Lilly and Company's CUSIP number? Eli Lilly and Company's Committee on Uniform Securities Identification Procedures number is: 532457108
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Advertiser disclosure
Finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which Finder receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. Finder compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
How likely would you be to recommend Finder to a friend or colleague?
0
1
2
3
4
5
6
7
8
9
10
Very UnlikelyExtremely Likely
Required
Thank you for your feedback.
Our goal is to create the best possible product, and your thoughts, ideas and suggestions play a major role in helping us identify opportunities to improve.
